Clinical comparison between neuroendocrine and endometrioid type carcinoma of the uterine corpus.
Adolescent
Adult
Aged
Aged, 80 and over
Carcinoma, Endometrioid
/ mortality
Cross-Sectional Studies
Endometrial Neoplasms
/ mortality
Female
Humans
Lymphatic Metastasis
Middle Aged
Neoplasm Staging
/ statistics & numerical data
Retrospective Studies
SEER Program
United States
/ epidemiology
Uterine Neoplasms
/ mortality
Young Adult
Endometrioid Adenocarcinoma
Neuroendocrine Tumor
Uterine Neoplasms
Journal
Journal of gynecologic oncology
ISSN: 2005-0399
Titre abrégé: J Gynecol Oncol
Pays: Korea (South)
ID NLM: 101483150
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
19
10
2018
revised:
28
12
2018
accepted:
24
01
2019
pubmed:
11
5
2019
medline:
10
3
2020
entrez:
11
5
2019
Statut:
ppublish
Résumé
To compare the clinicopathologic features and survival outcomes of neuroendocrine tumor of the uterine corpus (NET-U) to endometrioid type endometrial carcinoma (EC). From 1993 to 2012, the Surveillance, Epidemiology and End Results cancer registry was queried for women diagnosed with EC or NET-U. Data regarding stage, grade, presence of extra-uterine disease, lymph node metastasis, receipt of adjuvant radiation, surgical intervention and overall survival (OS) was extracted. Chi-square tests, t-tests and Kaplan Meir curves were used for statistical analysis. A total of 98,363 patients were identified: 98,245 with EC and 118 with NET-U. The mean age at diagnosis for EC was 61.7 years and 64.8 years for NET-U (p=0.01). NET-U cases were more likely to be poorly differentiated (97.0% vs. 15.6%; p≤0.01) and have nodal metastasis (56.4% vs. 11.1%; p≤0.01) when compared to EC. Presence of extrapelvic disease at the time of diagnosis was observed more frequently in NET-U compared to EC, 49.1% vs. 4.8%, respectively (odds ratio=18; 95% confidence interval=13.1-27.2; p≤0.01). Significant improvement in OS was observed in NET-U patient who received radiation (OS: 7.7 vs. 3.3 years; p≤0.01) or underwent surgical management (5.6 vs. 0.9 years; p≤0.01). The OS for EC was 14.4 vs. 4.6 years for NET-U (p≤0.01). NET-U represents an aggressive form of uterine malignancy. When compared to EC, patients with NET-U present at more advanced stage, have more frequent extra-uterine disease and lower OS.
Identifiants
pubmed: 31074241
pii: 30.e58
doi: 10.3802/jgo.2019.30.e58
pmc: PMC6543113
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e58Informations de copyright
Copyright © 2019. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology.
Déclaration de conflit d'intérêts
No potential conflict of interest relevant to this article was reported.
Références
Gynecol Oncol. 2003 Mar;88(3):333-9
pubmed: 12648583
J Clin Oncol. 2008 Jun 20;26(18):3063-72
pubmed: 18565894
Cancer. 1988 Oct 15;62(8):1586-93
pubmed: 3167773
Am J Surg Pathol. 1988 Sep;12(9):684-98
pubmed: 2458049
Arch Pathol Lab Med. 1997 Jan;121(1):34-9
pubmed: 9111090
BMC Cancer. 2018 May 4;18(1):530
pubmed: 29728073
Gynecol Oncol. 2011 Mar;120(3):444-8
pubmed: 21138780
Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S102-8
pubmed: 25341572
Am J Surg Pathol. 1994 Apr;18(4):364-75
pubmed: 7511354
Int J Gynecol Cancer. 2010 Apr;20(3):411-6
pubmed: 20375806
World J Gastroenterol. 2008 Sep 21;14(35):5377-84
pubmed: 18803349
Int J Gynecol Cancer. 2008 Jul-Aug;18(4):838-43
pubmed: 17868342
Gynecol Oncol. 2013 Apr;129(1):135-9
pubmed: 23357610
Gynecol Oncol. 2001 Apr;81(1):82-7
pubmed: 11277655
Gynecol Oncol. 2011 Jul;122(1):190-8
pubmed: 21621706
Am J Obstet Gynecol. 2010 Oct;203(4):347.e1-6
pubmed: 20579961
Am J Med Sci. 2010 Jan;339(1):68-76
pubmed: 19996730
Pancreas. 2019 Nov/Dec;48(10):1373-1379
pubmed: 31688604
Int J Gynecol Cancer. 2004 Sep-Oct;14(5):1018-23
pubmed: 15361218